Table 3 Comparison between group A and group B according to mRECIST at follow-up
mRECIST | Group A (n = 15) | Group B (n = 13) | Test of Sig. | p value |
|---|---|---|---|---|
At 1 month | ||||
CR | 2 (13.3%) | 4 (30.8%) | χ2 = 1.512 | 0.640 (MC) |
PR | 11 (73.3%) | 7 (53.8%) | ||
SD | 2 (13.3%) | 2 (15.4%) | ||
PD | 0 (0%) | 0 (0%) | ||
At 3 months | ||||
CR | 3 (20%) | 5 (38.5%) | χ2 = 4.775 | 0.250 (MC) |
PR | 6 (40%) | 6 (46.2%) | ||
SD | 0 (0%) | 1 (7.7%) | ||
PD | 5 (33.3%) | 1 (7.7%) | ||
Lost at follow-up | 1 (6.7%) | 0 (0%) | ||
At 6 months | ||||
CR | 4 (26.7%) | 7 (53.8%) | χ2 = 3.129 | 0.325 (MC) |
PR | 1 (6.7%) | 0 (0%) | ||
SD | 1 (6.7%) | 0 (0%) | ||
PD | 0 (0%) | 0 (0%) | ||
Lost at follow-up | 9 (60.0%) | 6 (46.2%) | ||
Overall survival | ||||
< 6 months | 3 (20%) | 1 (7.7%) | χ2 = 2.276 | 0.391 (MC) |
6–12 months | 7 (46.7%) | 4 (30.8%) | ||
> 12 months | 5 (33.3%) | 8 (61.5%) | ||
Mean ± standard deviation | 14.3 ± 10.6 | 22 ± 12.7 | U = 61.0 | 0.098 |
Median (minimum–maximum) | 10 (3–33) | 23 (3–42) | ||